PharmaPoint: Colorectal Cancer-Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer-Global Drug Forecast and Market Analysis to 2025


  • Products Id :- GDHC141PIDR
  • |
  • Pages: 465
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmaPoint: Colorectal Cancer-Global Drug Forecast and Market Analysis to 2025

Summary

The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change, following the approval of pipeline agents exploiting novel mechanisms of actions, especially immunotherapy. Some pipeline drug developers have invested heavily in the identification of potential predictive biomarkers; therefore, these novel agents are expected to induce further patient stratification and to add complexity to the CRC treatment algorithm, which will be also reshaped by the discovery of the predictive value of tumor sidedness.

Highlights

Key Questions Answered

The CRC market is characterized by a number of unmet needs in the current treatments. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?

The CRC market leader Avastin will experience competition from bevacizumab biosimilars, after its patent expiration in 2018. What will be the impact of bevacizumab biosimilars on the CRC market?

Nine late-stage pipeline agents are going to enter the CRC market from 2017 onwards. Will the late-stage drugs make a significant impact on the CRC market? Which of these drugs will have the highest peak sales, and why?

Key Findings

The main driver of the growth of the CRC market will be the increasing CRC incident cases, which is attributed to the aging population.

The second strongest driver will be the launch of several efficacious pipeline drugs in the metastatic setting, including immunotherapies that will enter the CRC landscape for the first time, and novel molecular-targeted agents, such as BRAF-targeted therapies.

To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate higher efficacy, in terms of overall survival (OS), compared with available agents. For this reason, almost all the new agents are expected to be positioned in the second- and third-line settings, in which the standard-of-care hurdle is lower.

The entrance of these agents in the CRC market will intensify the competition in the second-line metastatic setting onwards, which will be worsen by the launch of bevacizumab biosimilars, starting in 2018.

Scope

Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global CRC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global CRC therapeutics market from 2015-2025.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 9

1.1 List of Tables 16

1.2 List of Figures 22

2 Introduction 25

2.1 Catalyst 25

2.2 Related Reports 26

2.3 Upcoming Related Reports 26

3 Disease Overview 27

3.1 Etiology and Pathophysiology 27

3.1.1 Etiology 27

3.1.2 Pathophysiology 28

3.1.3 Biomarkers/ Targets of interest 29

3.2 Clinical Staging 32

3.3 Symptoms 34

3.4 Prognosis 34

3.5 Quality of Life 35

4 Epidemiology 37

4.1 Disease Background 37

4.2 Risk Factors and Comorbidities 37

4.3 Global Trends 39

4.3.1 8MM Incidence Trends 39

4.3.2 8MM, Trends in Five-Year Relative Survival 42

4.4 Forecast Methodology 43

4.4.1 Sources Used Tables 44

4.4.2 Forecast Assumptions and Methods 48

4.4.3 Sources Not Used 56

4.5 Epidemiological Forecast for CRC (2015-2025) 56

4.5.1 Diagnosed Incident Cases of CRC 56

4.5.2 Age-Specific Diagnosed Incident Cases of CRC 58

4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 60

4.5.4 Age-Standardized Diagnosed Incidence of CRC 62

4.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis 63

4.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC 64

4.5.7 Five-Year Diagnosed Prevalent Cases of CRC 65

4.6 Discussion 67

4.6.1 Epidemiological Forecast Insight 67

4.6.2 Limitations of the Analysis 69

4.6.3 Strengths of the Analysis 70

5 Disease Management 71

5.1 Diagnosis and Treatment Overview 71

5.1.1 Screening and Diagnosis 71

5.1.2 Treatment Guidelines and Leading Prescribed Drugs 77

5.1.3 Clinical Practice 81

5.2 US 97

5.2.1 Screening and Diagnosis 98

5.2.2 Clinical Practice 100

5.3 France 102

5.3.1 Screening and Diagnosis 103

5.3.2 Clinical Practice 104

5.4 Germany 106

5.4.1 Screening and Diagnosis 107

5.4.2 Clinical Practice 108

5.5 Italy 110

5.5.1 Screening and Diagnosis 111

5.5.2 Clinical Practice 112

5.6 Spain 114

5.6.1 Screening and Diagnosis 115

5.6.2 Clinical Practice 116

5.7 UK 118

5.7.1 Screening and Diagnosis 119

5.7.2 Clinical Practice 120

5.8 Japan 122

5.8.1 Screening and Diagnosis 123

5.8.2 Clinical Practice 124

5.9 China 126

5.9.1 Screening and Diagnosis 128

5.9.2 Clinical Practice 129

6 Competitive Assessment 131

6.1 Overview 131

6.2 Anti-angiogenesis drugs 132

6.2.1 Avastin (Bevacizumab) 134

6.2.2 Zaltrap (Ziv-Aflibercept) 146

6.2.3 Cyramza (Ramucirumab) 152

6.3 EGFR Targeted-therapies 157

6.3.1 Erbitux (Cetuximab) 159

6.3.2 Vectibix (Panitumumab) 168

6.4 Kinase Inhibitors 177

6.4.1 Stivarga (Regorafenib) 177

6.5 Chemotherapy 185

6.5.1 Lonsurf (Trifluridine + Tipiracil) 185

6.5.2 TS-1 (Tegafur + Gimeracil + Oteracil) 194

7 Unmet Need and Opportunity 199

7.1 Overview 199

7.2 Understanding and Overcoming Mechanisms of Resistance to Angionesis and EGFR Inhibitors 201

7.2.1 Unmet Need 201

7.2.2 Gap Analysis 203

7.2.3 Opportunity 204

7.3 Targeted Treatments for BRAF Mutation-Positive Patients 205

7.3.1 Unmet Need 205

7.3.2 Gap Analysis 206

7.3.3 Opportunity 206

7.4 Extending the Use of Immunotherapies to the MSS Population 207

7.4.1 Unmet Need 207

7.4.2 Gap Analysis 208

7.4.3 Opportunity 209

7.5 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 210

7.5.1 Unmet Need 210

7.5.2 Gap Analysis 211

7.5.3 Opportunity 212

7.6 Identification of Positive Predictive Biomarkers 213

7.6.1 Unmet Need 213

7.6.2 Gap Analysis 214

7.6.3 Opportunity 214

7.7 Additional and More Effective Later-Line Therapies for Chemotherapy-Resistant Patients 215

7.7.1 Unmet Need 215

7.7.2 Gap Analysis 216

7.7.3 Opportunity 217

8 Pipeline Assessment 218

8.1 Overview 218

8.2 Promising Drugs in Clinical Development 220

8.3 Immunotherapies 221

8.3.1 Lefitolimod (MGN-1703) 222

8.3.2 Keytruda (pembrolizumab) 229

8.3.3 Tecentriq (atezolizumab) 237

8.4 Molecular-Targeted Agents 245

8.4.1 Encorafenib (LGX-818) + Binimetinib (MEK-162) 245

8.4.2 Napabucasin (BBI-608) 254

8.4.3 Vargatef (Nintedanib) 261

8.4.4 Masitinib (AB-1010) 266

8.4.5 Fruquintinib (HMPL-013) 271

8.4.6 Famitinib (SHR-1020) 277

8.4.7 Donafenib (CM-4307) 282

8.5 Promising Approaches in Early Stage Development 285

8.5.1 Strategies to Overcome VEGF-Resistance 285

8.5.2 Strategies for BRAF Mutation-Positive Disease 288

8.5.3 Strategies for RAS-Mutation Positive Disease 293

8.5.4 Strategies to Overcome EGFR-Acquired Resistance 297

8.5.5 Immune Checkpoint Inhibitors Combinations 300

8.5.6 Other Strategies 304

8.5.7 Liver Directed Therapies 308

8.6 Biosimilars 311

8.6.1 Bevacizumab Biosimilars 314

8.6.2 Cetuximab Biosimilars 316

9 Current and Future Players 317

9.1 Overview 317

9.2 Trends in Corporate Strategy 321

9.3 Company Profiles 322

9.3.1 Amgen 322

9.3.2 Bayer 325

9.3.3 Eli Lilly and Company 328

9.3.4 Merck KGaA 331

9.3.5 Merck & Co. 333

9.3.6 Roche/Genentech 335

9.3.7 Taiho Pharmaceutical 339

10 Market Outlook 343

10.1 Global Markets 343

10.1.1 Forecast 343

10.1.2 Drivers and Barriers-Global Issues 346

10.2 United States 349

10.2.1 Forecast 349

10.2.2 Key Events 353

10.2.3 Drivers and Barriers 353

10.3 5 EU 356

10.3.1 Forecast 356

10.3.2 Key Events 359

10.3.3 Drivers and Barriers 359

10.4 Japan 362

10.4.1 Forecast 362

10.4.2 Key Events 365

10.4.3 Drivers and Barriers 365

10.5 China 368

10.5.1 Forecast 368

10.5.2 Key Events 371

10.5.3 Drivers and Barriers 371

11 Appendix 376

11.1 Bibliography 376

11.2 Abbreviations 431

11.3 Methodology 439

11.4 Forecasting Methodology 439

11.4.1 Diagnosed CRC Patients 440

11.4.2 Percent Drug-Treated Patients 441

11.4.3 Drugs Included in Each Therapeutic Class 441

11.4.4 Launch and Patent Expiry Dates 442

11.4.5 General Pricing Assumptions 443

11.4.6 Individual Drug Assumptions 445

11.4.7 Generic Erosion 453

11.4.8 Pricing of Pipeline Agents 454

11.5 Primary Research-KOLs Interviewed for this Report 456

11.6 Primary Research-Prescriber Survey 459

11.7 About the Authors 459

11.7.1 Analyst 459

11.7.2 Reviewers 460

11.7.3 Therapy Area Director 460

11.7.4 Epidemiologist 461

11.7.5 Reviewers 461

11.7.6 Global Head of Healthcare 463

11.8 About GlobalData 463

11.9 Disclaimer 464

1.2 List of Figures

Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages ?15 Years, 1998-2007 41

Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages ?15 Years, 1998-2007 42

Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ?18 Years, 2015-2025 58

Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ?18 Years, 2015 60

Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ?18 Years, 2015 62

Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ?18 Years, by Sex, 2015. 63

Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ?18 Years, 2015-2025 66

Figure 8: Treatment Flowchart for Regional or Locoregional CRC 84

Figure 9: Treatment Flowchart for mCRC 88

Figure 10: The Zurich Treatment Algorithm 92

Figure 11: Avastin's Development in CRC 138

Figure 12: Cyramza's Development in CRC 155

Figure 13: Erbitux's Development in CRC 162

Figure 14: Vectibix Development in CRC 171

Figure 15: Stivarga's Development in CRC 181

Figure 16: Lonsurf's Development in CRC 189

Figure 17: TS-1 Development in CRC 196

Figure 18: CRC-Phase III Pipeline, 2016 220

Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2015-2025 221

Figure 20: Lefitolimod's Clinical Development in CRC 224

Figure 21: Clinical and Commercial Positioning of Lefitolimod 227

Figure 22: Keytruda's Clinical Development in CRC 232

Figure 23: Clinical and Commercial Positioning of Keytruda 235

Figure 24: Tecentriq's Clinical Development in CRC 240

Figure 25: Clinical and Commercial Positioning of Tecentriq 243

Figure 26: Encorafenib's Clinical Development in CRC 249

Figure 27: Potential Clinical and Commercial Positioning for Encorafenib + BInimetinib 252

Figure 28: Napabucasin's Clinical Development in CRC 257

Figure 29: Clinical and Commercial Positioning of Napabucasin 259

Figure 30: Vargatef's Clinical Development in CRC 263

Figure 31: Clinical and Commercial Positioning of Vargatef 265

Figure 32:Masitinib's Clinical Development in CRC 268

Figure 33: Clinical and Commercial Positioning of Masitinib 270

Figure 34: Fruquintinib's Clinical Development in CRC 274

Figure 35: Clinical and Commercial Positioning of Fruquintinib 276

Figure 36: Famitinib's Clinical Development in CRC 279

Figure 37: Clinical and Commercial Positioning of Famitinib 281

Figure 38: Donafenib's Clinical Development in CRC 284

Figure 39: Clinical and Commercial Positioning of Donafenib 284

Figure 40: Clinical Development of Bevacizumab Biosimilars 315

Figure 41: Global Sales of Branded Products for CRC by Company, 2015-2025 320

Figure 42: Company Portfolio Gap Analysis in CRC, 2015-2025 321

Figure 43: Amgen SWOT Analysis in CRC, 2016 325

Figure 44: Bayer SWOT Analysis in CRC, 2016 327

Figure 45: Eli Lilly SWOT Analysis in CRC, 2016 330

Figure 46: Merck KGaA SWOT Analysis in CRC, 2016 333

Figure 47: Merck & Co. SWOT Analysis in CRC, 2016 335

Figure 48: Roche SWOT Analysis in CRC, 2016 339

Figure 49: Taiho SWOT Analysis in CRC, 2016 342

Figure 50: Global Sales for CRC by Region, 2015-2025 345

Figure 51: Global Sales for CRC by Drug Class, 2015-2025 346

Figure 52: Sales for CRC in the US, by Drug Class, 2015-2025 352

Figure 53: Sales for CRC in the 5EU, by Drug Class, 2015-2025 358

Figure 54: Sales for CRC in Japan, by Drug Class, 2015-2025 364

Figure 55: Sales for CRC in China by Drug Class, 2015-2025 370

1.1 List of Tables

Table 1: Stage Definitions for Colorectal Cancer 33

Table 2: Symptoms of CRC 34

Table 3: Prognosis for Colon and Rectal Cancer 35

Table 4: Risk Factors and Comorbidities For CRC 38

Table 5: 8MM, Five-Year Relative Survival (%) 43

Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC 44

Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC 45

Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis 45

Table 9: 8MM, Sources of Genetic Mutations 47

Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ?18 Years, 2015-2025 58

Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015 59

Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ?18 Years, Row (%), 2015 61

Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ?18 Years, Row (%), 2015 64

Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages ?18 Years, 2015 65

Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ?18 Years, 2015-2025 66

Table 16: Treatment Guidelines for CRC 77

Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016 78

Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016 79

Table 19: Country Profile-US 97

Table 20: Country Profile-France 102

Table 21: Country Profile-Germany 106

Table 22: Country Profile-Italy 110

Table 23: Country Profile-Spain 114

Table 24: Country Profile-UK 118

Table 25: Country Profile-Japan 122

Table 26: Country Profile-China 127

Table 27: Leading Treatments for CRC, 2016 132

Table 28: Product Profile-Avastin 135

Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL 139

Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy 141

Table 31: Summary of the Results of the ML18147 Study 142

Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX 142

Table 33: Summary of AEs from the AVF21070 trial of Avastin 144

Table 34: Avastin SWOT Analysis, 2016 145

Table 35: Product Profile-Zaltrap 147

Table 36: Summary of the Results from the VELOUR Study 150

Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap 151

Table 38: Zaltrap SWOT Analysis, 2016 152

Table 39: Product Profile-Cyramza 153

Table 40: Summary of the Phase III RAISE Trial of Cyramza 155

Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza 156

Table 42: Cyramza SWOT Analysis, 2016 157

Table 43: Product Profile-Erbitux 160

Table 44: Summary of the Result of the CRYSTAL Study 163

Table 45: Summary of the Results of the CRYSTAL Study-BRAF Mutation 164

Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux 165

Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux 166

Table 48: Erbitux SWOT Analysis, 2016 167

Table 49: Product Profile-Vectibix 168

Table 50: Summary of the Results from the PRIME Trial of Vectibix 172

Table 51: Summary of the Results from the PEAK Study of Vectibix 173

Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy 174

Table 53: Summary of the Results from the ASPECCT Study of Vectibix 174

Table 54: Incidence of Grade 3-4 AEs of the PRIME Trial of Vectibix 175

Table 55: Vectibix SWOT Analysis, 2016 176

Table 56: Product Profile-Stivarga 177

Table 57: Summary of the Results from the CORRECT Study of Stivarga 181

Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga 183

Table 59: Stivarga SWOT Analysis, 2016 184

Table 60: Product Profile-Lonsurf 186

Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf 190

Table 62: Summary of the AEs in the Phase III Trial of Lonsurf 192

Table 63: Lonsurf SWOT Analysis, 2016 193

Table 64: Product Profile-TS-1 194

Table 65: Summary of a Phase III trial of TS-1 196

Table 66 Summary of Most Common AEs in a Phase III Trial of TS-1 197

Table 67: TS-1 SWOT Analysis, 2016 198

Table 68: Unmet Needs and Opportunities in CRC 201

Table 69: Product Profile-Lefitolimod 222

Table 70: Summary of the IMPACT Trial of Lefitolimod 225

Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod 226

Table 72: Lefitolimod SWOT Analysis, 2016 228

Table 73: Product Profile-Keytruda 229

Table 74 Summary of the Results of the Phase II Trial of Keytruda 233

Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda 234

Table 76: Keytruda SWOT analysis, 2016 236

Table 77: Product Profile-Tecentriq 237

Table 78: Summary of the Phase Ib Trial of Tecentriq 241

Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq 242

Table 80: Tecentriq SWOT analysis, 2016 244

Table 81: Product Profile-Encorafenib +Binimetinib 245

Table 82: Summary of the Results from the Phase II Trial of Encorafenib 249

Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib 251

Table 84: Encorafenib + binimetinib-SWOT Table, 2016 253

Table 85: Product Profile-Napabucasin 254

Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin 257

Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix 258

Table 88: Napabucasin, SWOT Analysis, 2016 260

Table 89: Product Profile-Vargatef 261

Table 90: Summary of the Result of the Phase III LUME Colon-1 Trial of Vargatef 264

Table 91: Vargatef SWOT Analysis, 2016 265

Table 92: Product Profile-Masitinib 266

Table 93: Summary of the Results of the Phase II Trial of Masitinib 269

Table 94: Masitinib SWOT Analysis, 2016 271

Table 95: Product Profile-Fruquintinib 272

Table 96: Summary of the Results of the Phase II Trial of Fruquintinib 274

Table 97: Summary of Frequent AEs in the Phase II trial of Fruquintinib 275

Table 98: Fruquintinib SWOT Analysis, 2016 277

Table 99: Product Profile-Famitinib 278

Table 100: Summary of the Results of the Phase II Trial of Famitinib 280

Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib 280

Table 102: Famitinib SWOT Analysis, 2016 282

Table 103: Product Profile-Donafenib 283

Table 104: Donafenib SWOT Analysis, 2016 285

Table 105: Promising strategies to overcome VEGF resistance 286

Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC 290

Table 107: Early-stage Strategies for KRAS Mutation-Positive CRC 295

Table 108: Early-Stage Strategies for EGFR Acquired Resistance 298

Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC 302

Table 110: CAR-T Cell Therapies Under Development 305

Table 111: Vaccines in Development in CRC 307

Table 112: Radioembolization Tecnhiquese Evaluated for the Treatment of Colorectal Cancer Liver Metastasis 309

Table 113: List of Bevacizumab Biosimilars in Phase III Development 314

Table 114: Key Companies in the CRC Market in the 8MM, 2015-2025 319

Table 115: Amgen's CRC Portfolio Assessment, 2016 324

Table 116: Bayer's CRC Portfolio Assessment, 2016 327

Table 117: Eli Lilly's CRC Portfolio Assessment, 2016 330

Table 118: Merck KGaA's CRC Portfolio Assessment, 2016 332

Table 119: Merck & Co.'s CRC Portfolio Assessment, 2016 335

Table 120: Roche's CRC Portfolio Assessment, 2016 338

Table 121: Taiho's CRC Portfolio Assessment, 2016 341

Table 122: CRC Market Drivers and Barriers, 2016 346

Table 123: Key Events Impacting Sales for CRC in the US, 2015-2025 353

Table 124: US CRC Market Drivers and Barriers, 2016 353

Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015-2025 359

Table 126: 5EU CRC Market Drivers and Barriers, 2016 359

Table 127: Key Events Impacting Sales for CRC in Japan, 2015-2025 365

Table 128: Japan CRC Market-Drivers and Barriers, 2016 365

Table 129: Key Events Impacting Sales for CRC in China, 2015-2025 371

Table 130: China CRC Market-Drivers and Barriers, 2016 371

Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer 442

Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer 443

Table 133 Average Body Weight and Surface Area Across the 8MM 445

Table 134: Treatment Duration in Colorectal Cancer 445

Table 135: Average Cost of Therapy of Avastin in the 8MM 446

Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM 448

Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China) 449

Table 138: Average Cost of Therapy of Erbitux in the 8MM 450

Table 139: Average Cost of Therapy of Lonsurf in the 8MM 451

Table 140: Average Cost of Therapy of Stivarga in the 8MM 452

Table 141: Average Cost of Therapy of Vectibix in the 8MM 452

Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU 453

Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 459

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science , Amgen , Array BioPharma , AstraZeneca , Bayer , Biocad , Boehringer Ingelheim , Bristol-Myers Squibb , BTG International , Daiichi-Sankyo , Cleveland Biolabs , Eli Lilly , GlaxoSmithKline , Gradalis , Hutchinson Medi Pharma , Immunomedics , Immunovative Therapies , Jiangsu Hengrui , Merck KGaA , Merck & Co. , Merrimack , Mologen , Novartis , PsiOxus therapeutics , Roche/Genentech , Sanofi , Sorrento , Sirtex , Sumitomo Dainippon Pharma , Suzhou Zelgen , Symphogen , Taiho Pharmaceuticals , Takeda , Tracon Pharmaceuticals

select a license

Single User License
USD 10995 INR 708958
Site License
USD 21990 INR 1417915
Corporate User License
USD 32985 INR 2126873

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com